Get the StoQuant digest — free
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks.
Email only, no account needed. See a sample digest.
CLLS vs GSK — Stock Comparison
Compare CLLS and GSK side-by-side on StoQuant: CLLS Q-Score 50 vs GSK 31; analyst signal — vs 55. Plus alt data signals, insider buying, catalysts, strategic edges, short interest, social sentiment, and macro context.
Side-by-side snapshot
- CLLS — Cellectis S.A. · Health Care · market cap $142M · Q-Score verdict Unrated (50.0) · strongest signals: technicals 27/100. Full CLLS research.
- GSK — GSK plc · Health Care · market cap $93.37B · Q-Score verdict Sell (31.0, grade D) · analyst signal 55/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: technicals 25/100, analyst consensus 23/100. Full GSK research.
What you can compare
- Q-Score: StoQuant's composite 0–100 rating based on 140+ financial signals.
- Alt data signals: Google Trends, EDGAR 8-K filings, job postings, and more.
- Insider activity: Cluster scores and recent Form 4 buying.
- Catalysts: Earnings, analyst changes, M&A, clinical trials, and SEC events.
- Strategic edges: Competitive moat and durable advantage analysis.
- Short interest & social sentiment: Short % float, social mention volume, and bullish/bearish breakdown.
- Macro context: Market regime and sector rotation alignment.
Deep dive: CLLS research · GSK research. Sign in to StoQuant to run live comparisons for any tickers.